Harrow launches $250M senior notes offering, enters $40M revolver, and discloses Melt Pharmaceuticals acquisition plan

HARROW, INC.

Launched $250M offering of senior unsecured notes due 2030 to refinance existing debt, including redemption of 2026 Notes (8.625%, $75M) and 2027 Notes (11.875%, $40.25M).
Entered commitment for $40M revolving credit facility with Fifth Third Bank, secured by substantially all assets, maturing 91 days before 2030 Notes maturity or five years from closing.
Issued conditional notice to redeem all $40.25M 2027 Notes at 102% of par plus accrued interest on Oct 9, 2025, contingent on completion of the Offering.
Plans to redeem $75M 2026 Notes at 100% plus make-whole, and repay $107.5M Oaktree loan, with remaining proceeds for general corporate purposes.
Disclosed non-binding LOI to acquire remaining 55% of Melt Pharmaceuticals for ~$4.3M cash at close plus contingent milestones; CEO and CFO hold Melt interests.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.